Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-114224
Filing Date
2025-09-11
Accepted
2025-09-11 16:11:26
Documents
72
Period of Report
2025-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q engn-20250731.htm   iXBRL 10-Q 2367732
2 EX-10.6 engn-ex10_6.htm EX-10.6 133574
3 EX-10.7 engn-ex10_7.htm EX-10.7 134900
4 EX-31.1 engn-ex31_1.htm EX-31.1 22894
5 EX-31.2 engn-ex31_2.htm EX-31.2 22548
6 EX-32.1 engn-ex32_1.htm EX-32.1 11828
7 EX-32.2 engn-ex32_2.htm EX-32.2 11817
  Complete submission text file 0000950170-25-114224.txt   10414552

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20250731.xsd EX-101.SCH 1593362
74 EXTRACTED XBRL INSTANCE DOCUMENT engn-20250731_htm.xml XML 1873647
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 251308655
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)